PFIZER INC - 01 Aug 2024 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc.

Reporting relationship: Former 10% Owner
Issuer ticker: N/A
Reported as of: 01 Aug 2024
Net transaction value: -$1,230,714,495
SEC form: 4
Accepted by SEC: 05 Aug 2024, 18:25:19 UTC
Prior SEC filing: 30 Mar 2023
Source filing: View source filing
Reporting owner signature: Pfizer Inc. by /s/ Susan Grant, Assistant Secretary

Key filing fact

PFIZER INC filed Form 4 for Cerevel Therapeutics Holdings, Inc. on 05 Aug 2024.

Key facts

This page summarizes PFIZER INC's Form 4 filing for Cerevel Therapeutics Holdings, Inc..
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 05 Aug 2024, 18:25.

Change

Previous filing in this sequence was filed on 30 Mar 2023.
Current net transaction value: -$1,230,714,495.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CERE transaction

Common Stock

Disposition pursuant to a tender of shares in a change of control transaction

Transaction value: $1,230,714,495
Shares: -27,349,211
Change %: -100%
Price: $45.00
Shares after: 0
Date: 01 Aug 2024
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

PFIZER INC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 1 footnote

Footnote F1

Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("AbbVie"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of AbbVie upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest.